Oriola is a pharmaceutical group with a particular focus on the distribution of pharmaceuticals to other players in the industry. The company offers services to pharmacies and other pharmaceutical companies, which includes, for example, negotiations with suppliers and distribution of products. The largest operations are in the Nordic and Baltic regions. The headquarters are located in Espoo.
Higher freight costs and increased operating expenses weighed on Oriola's earnings in Q2. Meanwhile, associate company Kronans improved its result compared with the corresponding period last year.
Oriolas Q2-regnskab var operationelt en smule svagere end vores forventninger, da selskabets justerede EBITDA forblev på niveau med sammenligningsperioden og var lidt lavere end vores estimater.
With the financial targets announced earlier along with major investments known, Oriola’s CMD was limited in terms of significant new news, which we see as a positive given earlier concerns. More clarity was however provided on the roadmap to achieving...
Oriola offentliggjorde allerede i forbindelse med regnskabsmeddelelsen for 1. kvartal nye finansielle mål, som vil blive præsenteret yderligere på kapitalmarkedsdagen den 12. maj.
